Posted by Michael Wonder on 26 Aug 2021
PHARMAC seeks feedback on a biosimilar brand of adalimumab being considered for funding
26 August 2021 - PHARMAC is considering awarding Principal Supply to a biosimilar brand of adalimumab (Amgevita) from 1 February 2022.
Adalimumab, as Humira, is already funded for a number of gastroenterology, rheumatology, dermatology and ophthalmology conditions.
